Filing Details
- Accession Number:
- 0001209191-17-041062
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-06-20 16:07:09
- Reporting Period:
- 2017-06-17
- Filing Date:
- 2017-06-20
- Accepted Time:
- 2017-06-20 16:07:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
816284 | Celgene Corp | CELG | Pharmaceutical Preparations (2834) | 222711928 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1190435 | D Michael Casey | C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-06-17 | 333 | $0.00 | 0 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2017-06-19 | 9,250 | $125.59 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Disposition | 2017-06-17 | 333 | $0.00 | 333 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
334 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 92,070 | Indirect | Family Trust |
Footnotes
- One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock.
- The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $125.57 to $125.60, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- The balance of the restricted stock units will vest on June 17, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date.
- The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)).